Cancer Monoclonal Antibodies Market: By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain cancer, Colorectal Cancer, Other), By Type of Antibody (Murine Antibodies, Humanized Antibodies, Chimeric Antibodies), By Conjugation (Immunocytokines, Immunoliposome, Radioimmunotherapy, Antibody Directed Enzyme Prodrug Therapy(ADEPT)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacie, Online Pharmacies) and By Geography.

Cancer Monoclonal Antibodies Market size was valued at USD 47.2 billion and is expected to grow at a CAGR of 11.8% from 2023-2029. A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of a cancer cell when the antibody binds to an antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have the least adverse effects than other cancer-treating drugs. Currently cancer monoclonal antibodies market is witnessing significant growth. Targeted and combination therapy drugs are leading in the market. Several market players collaborating to develop antibody drugs to treat various types of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for a new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function-modulating antibodies against undisclosed membrane protein targets. Academic institutions and organizations like the National Institute of Health (USA), the National Cancer Institute (USA), and many others are collaborating and participating in cancer research and awareness activities.

Cancer Monoclonal Antibodies Market Key Developments:

In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca's durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology's tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.